DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, British Columbia, Canada V5Z 1K5
February 19, 2019
VIA EDGAR SUBMISSION
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
| Re: | REQUEST FOR ACCELERATION OF EFFECTIVENESS | |
| DelMar Pharmaceuticals, Inc. | ||
| Registration Statement on Form S-3 | ||
| File No. 333-229020 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement to Tuesday, February 19, 2019, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.
Thank you for your assistance. If you should have any questions, please contact Steven M. Skolnick of Lowenstein Sandler LLP, counsel to the Registrant, at (212) 262-6700.
| Very truly yours, | ||
| DelMar Pharmaceuticals, Inc. | ||
| By: | /s/ Saiid Zarrabian | |
| Name: | Saiid Zarrabian | |
| Title: | Chief Executive Officer | |
